AstraZeneca $425M Deal : Gastric Acid Drugs

0
163

The saga didn’t end there. Subsequent research, akin to pulling threads from a tapestry, revealed stronger ties. A groundbreaking scientific study unfurled in January 2016, laying bare an alarming association. The findings? Use of these proton-pump inhibitors surged the risks of chronic kidney disease by a staggering 20% to 50%.